Drug testing. Massive trial of Celebrex seeks to settle safety concerns.
Couzin
Jennifer
J
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D000068579:Celecoxib; D015986:Confounding Factors, Epidemiologic; D051545:Cyclooxygenase 1; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004347:Drug Interactions; D006331:Heart Diseases / Q000188:drug therapy*; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use; D008565:Membrane Proteins / Q000037:antagonists & inhibitors; D009288:Naproxen / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000941:ethics / Q000379:methods / Q000592:standards; D012107:Research Design; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D009288:Naproxen; D051545:Cyclooxygenase 1; C496511:PTGS1 protein, human; D000068579:Celecoxib; D001241:Aspirin; D007052:Ibuprofen